Addition of bisphosphonate to antibiotic and anti‐inflammatory treatment reduces bone resorption in experimental Staphylococcus aureus‐induced arthritis

Bacterial arthritis is a disease with high morbidity leading to rapidly progressive bone resorption. We have shown earlier that treatment with antibiotics in combination with corticosteroids decreases joint inflammation and mortality but does not significantly affect bone/cartilage destruction of the joints. This study was performed to assess the effect of treatment with bisphosphonate [zoledronic acid (ZA)] in combination with antibiotics and corticosteroids, on the course and outcome of Staphlococcus aureus‐induced arthritis. Three days after intravenous inoculation with S. aureus, mice were treated with antibiotics alone, ZA alone, ZA and antibiotics, or ZA combined with antibiotics and corticosteroids, respectively. One group served as controls and received PBS. Clinical assessment of arthritis was performed as well as histological analysis of bone and cartilage destruction in the joints. One femur from each mouse was collected for bone mineral density (BMD) analysis. In addition, serum levels of type I collagen fragments (RatLaps), and osteocalcin, markers for osteoclastic and osteoblastic activity, respectively, were analyzed. Mice treated with ZA and antibiotics or with ZA in combination with antibiotics and corticosteroids lost significantly less in trabecular bone density compared to infected control mice. Furthermore, the addition of corticosteroids to animals treated with ZA and antibiotics, significantly decreased serum levels of RatLaps and osteocalcin, compared to animals treated with ZA and antibiotics or ZA alone. Treatment with bisphosphonates in combination with antimicrobial agents and corticosteroids significantly decreases the activity of osteoclasts in septic arthritis, thereby reducing the risk of skeletal destruction. © 2006 Orthopaedic Research Society. Published by Wiley Periodicals, Inc. J Orthop Res

[1]  C. Ohlsson,et al.  Osteoporosis in experimental postmenopausal polyarthritis: the relative contributions of estrogen deficiency and inflammation , 2005, Arthritis research & therapy.

[2]  T. Martin,et al.  Targeting osteoclasts with zoledronic acid prevents bone destruction in collagen-induced arthritis. , 2004, Arthritis and rheumatism.

[3]  K. Pettersson,et al.  Release of Intact and Fragmented Osteocalcin Molecules from Bone Matrix during Bone Resorption in Vitro* , 2004, Journal of Biological Chemistry.

[4]  A. Abdelnour,et al.  Double blind, randomized, placebo-controlled study of dexamethasone therapy for hematogenous septic arthritis in children , 2003, The Pediatric infectious disease journal.

[5]  R. Oberbauer,et al.  Zoledronic acid to prevent bone loss in the first 6 months after renal transplantation. , 2003, Kidney international.

[6]  R. Keen,et al.  Zoledronate treatment in active Paget’s disease , 2003, Annals of the rheumatic diseases.

[7]  M. Shirtliff,et al.  Acute Septic Arthritis , 2002, Clinical Microbiology Reviews.

[8]  M. Cutolo,et al.  Serum Osteocalcin Levels in Premenopausal Rheumatoid Arthritis Patients , 2002, Annals of the New York Academy of Sciences.

[9]  R. Landes,et al.  Promotion of osteoclast survival and antagonism of bisphosphonate-induced osteoclast apoptosis by glucocorticoids. , 2002, The Journal of clinical investigation.

[10]  Jacques P. Brown,et al.  Intravenous zoledronic acid in postmenopausal women with low bone mineral density. , 2002, The New England journal of medicine.

[11]  A. Howell,et al.  Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. , 2001, Cancer journal.

[12]  A. Tarkowski,et al.  Model systems: modeling human staphylococcal arthritis and sepsis in the mouse. , 2001, Trends in microbiology.

[13]  J. Ingle,et al.  Bisphosphonates directly regulate cell proliferation, differentiation, and gene expression in human osteoblasts. , 2000, Cancer research.

[14]  P. Roberson,et al.  Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin. , 1999, The Journal of clinical investigation.

[15]  J. Gustafsson,et al.  Increased cortical bone mineral content but unchanged trabecular bone mineral density in female ERbeta(-/-) mice. , 1999, The Journal of clinical investigation.

[16]  M. Rogers,et al.  Bisphosphonates: from the laboratory to the clinic and back again. , 1999, Bone.

[17]  S. Olusi,et al.  Serum concentrations of interleukin 6, osteocalcin, intact parathyroid hormone, and markers of bone resorption in patients with rheumatoid arthritis. , 1999, The Journal of rheumatology.

[18]  G. Passeri,et al.  Bisphosphonates inhibit IL-6 production by human osteoblast-like cells. , 1998, Scandinavian journal of rheumatology.

[19]  A. Tarkowski,et al.  Addition of corticosteroids to antibiotic treatment ameliorates the course of experimental Staphylococcus aureus arthritis. , 1996, Arthritis and rheumatism.

[20]  M. Nousiainen,et al.  Internalization of Staphylococcus aureus by cultured osteoblasts. , 1995, Microbial pathogenesis.

[21]  A. Hattersley,et al.  Oral and inhaled corticosteroids reduce bone formation as shown by plasma osteocalcin levels. , 1995, American journal of respiratory and critical care medicine.

[22]  A. Tarkowski,et al.  The accessory gene regulator (agr) controls Staphylococcus aureus virulence in a murine arthritis model , 1993, Infection and immunity.

[23]  A. Tarkowski,et al.  Histopathological and serological progression of experimental Staphylococcus aureus arthritis , 1992, Infection and immunity.

[24]  A. Tarkowski,et al.  Outbreak of spontaneous staphylococcal arthritis and osteitis in mice. , 1990, Arthritis and rheumatism.

[25]  L. Aarden,et al.  Functional discrimination between interleukin 6 and interleukin 1 , 1988, European journal of immunology.

[26]  J. Dequeker,et al.  Increased levels of osteocalcin (serum bone Gla-protein) in rheumatoid arthritis. , 1986, British journal of rheumatology.